This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Ecole Normale Superieure De Lyon, Hospices Civils De Lyon. Active years: 2017.
Company Filing History:
1 out of 5,383 
1 out of 44 
1 out of 46 
Years Active: 2017
Title: The Innovations of David Egron
Introduction
David Egron is a notable inventor based in Grabels, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic compounds. His work focuses on the creation of 5'-nucleotidase inhibitors, which have potential applications in oncology.
Latest Patents
David Egron holds a patent for compounds featuring a 6-aminopurine backbone, which are designed for use in the treatment of cancer. The patent details the specific formula of these compounds, where R, R, R, X, Y, and Z are defined in the claims. The invention aims to provide new therapeutic options for patients suffering from cancer.
Career Highlights
Throughout his career, David Egron has worked with prestigious institutions, including the Centre National de la Recherche Scientifique and Hospices Civils de Lyon. His experience in these organizations has allowed him to advance his research and contribute to significant scientific advancements.
Collaborations
David has collaborated with esteemed colleagues such as Laurent Chaloin and Suzanne Peyrottes. These partnerships have enriched his research and fostered innovation in the field of cancer therapeutics.
Conclusion
David Egron's work exemplifies the impact of innovative research in the medical field. His contributions to cancer treatment through the development of 5'-nucleotidase inhibitors highlight the importance of continued exploration and invention in healthcare.